Hussain M, Tangen CM, Berry DL, Higano CS, et al. The New England Journal of Medicine. Apr 4, 2013.
“Castration resistance occurs in most patients with metastatic hormone-sensitive prostate cancer who are receiving androgen-deprivation therapy. Replacing androgens before progression of the disease is hypothesized to prolong androgen dependence…”
A natural, nontoxic product called genistein-combined polysaccharide which is commercially available in health stores, could help lengthen the life expectancy of certain prostate cancer patients, UC Davis researchers have found. The findings hold promise for the product as a way to extend life expectancy of patients with low response to androgen-deprivation therapy. TThe product is a proprietary extract cultured from soybeans and shiitake mushrooms that was found to help block a key mechanism used by prostate cancer cells to survive in the face of testosterone deprivation.
A study based in Quebec, Canada, evaluated 630 patients undergoing hormone therapy for localized, high-risk prostate cancer. The study compared 18 months of hormone therapy to the standard treatment length of 36 months and found no significant difference in survival between the two treatment groups. Some researchers feel more data is necessary to draw a final conclusion.
In a phase I clinical trial, a new drug called ODM-201 was found to be effective and well tolerated by men with prostate cancer. Preclinical studies indicate that the androgen receptor-blocking drug may be more potent than the recently approved drug enzalutamide. The phase I clinical trial has been expanded and a phase II clinical trial is ongoing.
Results of a clinical trial that evaluated the prostate cancer vaccine Provenge have come under scrutiny. Questions arise regarding the reported 4-month survival benefit that ultimately led to FDA approval. Disputers suggest that a flaw in methods led to the survival benefit, but that the vaccine may actually cause harm.
A recent study evaluated the usefulness of surgery versus observation to treat localized prostate cancer. In the study, 731 men were followed for 10 years. Those treated with surgery did not have a significant decreased risk of death compared to those who were observed for advancing cancer.
A recent study weighed the benefits of yearly prostate cancer screening, finding that the potential disadvantages decrease the potential advantages by 23%. Harmful results of yearly prostate screening include negative prostate biopsies, radical prostatectomy, and radiation therapy.
A recent study found a relationship between the SPARCL1 gene and prostate cancer recurrence. Individuals who had lower activity of the gene had a higher risk of prostate cancer recurrence over 10 years. A test to detect SPARCL1 is being designed.
The New England Journal of Medicine | Oct 25, 2012
The utility of (prostate-specific antigen) PSA screening to inform prostate cancer diagnosis and treatment has been a topic of heated debate. The New England Journal of Medicine (NEJM) conducted a poll that indicates a lack of consensus among clinicians regarding best prostate cancer screening practices. Many clinicians feel patients should make informed decisions regarding testing preferences.